ExPERT Interview: Developing a GMP-Compatible, Large-Scale CAR T Cell Manufacturing with nS/MARt Vectors

The DNA Vector Lab at the German Cancer Research Center (DKFZ) has developed Nano-S/MARt (nS/MARt), a novel DNA Vector platform that combines prolonged CAR/TCR expression with minimal disruption of T cell activity. This antibiotic-free, nanovector technology uses scaffold/matrix attachment regions (S/MARs) for DNA vector maintenance and replication and it can be introduced efficiently into primary human T Cells without toxicity. When combined with GMP-compliant MaxCyte Flow Electroporation® and CliniMACS Prodigy™ automated cell processing, nS/MARt enables the production of clinically relevant recombinant CAR or TCR T cells with enhanced anti-tumor activity in a single week.

 

Learning Objectives